Fig. 2

Radiographic response assessment for patients with unresectable HCC receiving combined treatment with a tyrosine kinase inhibitor and an anti–PD-1 antibody as assessed by mRECIST. Each bar represents 1 patient. The blue bars indicate patients who achieved a pCR, and the red bars indicate those who did not achieve a pCR after systemic therapy. The intrahepatic tumor of Patient 1 was evaluated as a PR; however, a new metastatic lesion was found in the right adrenal gland during systemic therapy. HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; pCR, pathologic complete response; PD-1, programmed death 1